GOLDMAN SACHS GROUP INC - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 128 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.4%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$16,434,265
+48.3%
552,598
-10.1%
0.00%
+50.0%
Q2 2023$11,079,525
+32.6%
614,846
+18.2%
0.00%0.0%
Q1 2023$8,354,379
+242.4%
520,198
+290.2%
0.00%
+100.0%
Q4 2022$2,439,683
+1.3%
133,316
+8.7%
0.00%0.0%
Q3 2022$2,409,000
+32.6%
122,668
+25.9%
0.00%
Q2 2022$1,817,000
-25.2%
97,453
-11.9%
0.00%
-100.0%
Q1 2022$2,428,000
+38.9%
110,603
+79.8%
0.00%
Q4 2021$1,748,000
+49.8%
61,520
+11.0%
0.00%
Q3 2021$1,167,000
+1.7%
55,425
-8.8%
0.00%
Q2 2021$1,147,000
-38.7%
60,805
-50.3%
0.00%
Q1 2021$1,870,000
+3.4%
122,352
-4.5%
0.00%
Q4 2020$1,809,000
+13.8%
128,182
+26.4%
0.00%
Q3 2020$1,589,000
+545.9%
101,392
+622.0%
0.00%
Q2 2020$246,000
-77.5%
14,043
-80.7%
0.00%
Q3 2019$1,093,000
-75.8%
72,640
-59.9%
0.00%
-100.0%
Q2 2019$4,525,000
+1279.6%
180,990
+1157.7%
0.00%
Q1 2019$328,000
-0.3%
14,391
+31.1%
0.00%
Q4 2018$329,00010,9740.00%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q1 2023
NameSharesValueWeighting ↓
Saturn V Capital Management LP 623,819$11,336,5019.41%
Finepoint Capital LP 822,745$15,0564.87%
Bain Capital Life Sciences Investors, LLC 2,305,558$42,1924.72%
Opaleye Management Inc. 732,000$13,395,6004.66%
5AM Venture Management, LLC 862,286$15,779,8344.24%
SPHERA FUNDS MANAGEMENT LTD. 671,644$12,291,0852.64%
First Light Asset Management, LLC 1,329,313$24,326,4282.26%
BRAIDWELL LP 3,469,674$63,495,0342.13%
BVF INC/IL 2,736,613$50,080,0182.11%
Perceptive Advisors 4,039,276$73,918,7512.08%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders